Paul B Manning bought $18M of VRCA
director, owner at Verrica Pharmaceuticals Inc.. 4,126,142 shares at an average of $4.24, traded Nov 25, 2025, filed Nov 25, 2025.
Score components
- +15RoleDirector
- +25Trade size$17.5M at market
- +10Relative to holdingsHoldings up 160%
- +8Price context60% below the 52-week high
- +15Cluster5 insiders buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001494695-25-000004, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Nov 25, 2025 | POpen-market purchase Common Stock | +1,375,380 | $4.24 | $5.8M | 3,958,189 | Nov 25, 2025 |
| Nov 25, 2025 | POpen-market purchase Common Stockindirect: See footnote | +2,750,762 | $4.24 | $12M | 3,348,372 | Nov 25, 2025 |
| Nov 25, 2025 | POpen-market purchase Series C Warrant (right to buy)derivative | +343,845 | - | - | 343,845 | Nov 25, 2025 |
| Nov 25, 2025 | POpen-market purchase Series C Warrant (right to buy)derivativeindirect: See footnote | +687,690 | - | - | 687,690 | Nov 25, 2025 |
Related signals
Other insiders at Verrica Pharmaceuticals Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 55Moderate | Verrica Pharmaceuticals Inc. | John J. Kirby Interim CFO | $15k 3,536 shares | +65% | |
| 74Notable | Verrica Pharmaceuticals Inc. | Jayson Rieger CEO and President | $400k 94,311 shares | +107% | |
| 46Moderate | Verrica Pharmaceuticals Inc. | Noah L. Rosenberg CMO | $10,000 2,357 shares | - | |
| 59Moderate | Verrica Pharmaceuticals Inc. | David Zawitz Chief Operating Officer | $42k 10,000 shares | +91% | |
| 15Weak | VRCAsell Verrica Pharmaceuticals Inc. | Christopher G. Hayes CHIEF LEGAL OFFICER | $2,805 4,315 shares | -2% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.